ARTV Earnings Date: Nov 11, 2026 (Estimated) — Artiva Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ARTV's next earnings date?
Artiva Biotherapeutics, Inc. (ARTV) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.54.
How did ARTV do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Artiva Biotherapeutics, Inc. posted EPS of -$0.63 versus the -$0.63 estimate, a miss of 1.6%. Revenue was $0. The stock's 1-day post-earnings move was -2.7%.
How much does ARTV stock move after earnings?
ARTV beat EPS estimates in 0 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.0% (up or down) in the day after earnings.
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.63 | -0.63 | +1.56% | $0 | ❌ Miss | -2.68% | -2.42% | -3.37% |
| 2026-05-08 | Q1 2026 | -0.85 | -0.95 | -11.76% | $0 | ❌ Miss | -13.02% | -14.70% | -45.69% |
| 2026-03-10 | Q4 2025 | -0.83 | -0.84 | -1.20% | $0 | ❌ Miss | +6.48% | +8.23% | +8.41% |
| 2025-11-12 | Q3 2025 | -0.85 | -0.88 | -3.53% | $0 | ❌ Miss | +10.86% | +8.36% | -12.53% |
| 2025-08-06 | Q2 2025 | -0.80 | -0.87 | -8.75% | $0 | ❌ Miss | -8.01% | -6.97% | +25.78% |
| 2025-05-08 | Q1 2025 | -0.66 | -0.83 | -25.76% | $0 | ❌ Miss | +3.81% | -13.81% | +0.00% |
| 2025-03-24 | Q4 2024 | -0.62 | -0.66 | -6.45% | $0 | ❌ Miss | -8.43% | -26.00% | -42.62% |
| 2024-11-12 | Q3 2024 | -0.91 | -0.92 | -1.10% | $0 | ❌ Miss | -10.48% | -13.54% | -18.29% |
Showing last 8 quarters.